Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DXS InternationalSTU:7EE 39 Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus rates STU:7EE with a GF Score™ of 39/100 and a GF Value™ of €0.02. The stock has 2 warning signs investors should review. Among 273 Healthcare Providers & Services companies, DXS International ranks worse than 366300% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for DXS International's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7EE vs VEEV, BTSG, TEM: Buyback Yield % Comparison
For the Health Information Services subindustry, DXS International's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DXS International Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DXS International's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where DXS International's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DXS International (STU:7EE) has a Buyback Yield % of 0.00 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DXS International and its competitors. According to the industry distribution chart, DXS International ranks #999999 out of 273 companies in the Healthcare Providers & Services industry.
Is DXS International's Buyback Yield % too high?
DXS International's current Buyback Yield % is 0.00. Based on the distribution chart, DXS International ranks #999999 out of 273 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DXS International has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does DXS International's Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #999999 out of 273 companies for Buyback Yield %. This places DXS International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DXS International and its competitors. DXS International's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
DXS International (STU:7EE) has a current Buyback Yield % of 0.00. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 45% below its estimated fair value. The current Buyback Yield % is 0.00. DXS International's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For DXS International (STU:7EE), the current Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DXS International (STU:7EE) Overvalued in 2026?
Based on GuruFocus' analysis, DXS International stock appears to be undervalued.
The current stock price of €0.01 is trading 45% below its estimated GF Value™ of €0.02.
Key valuation signals for STU:7EE:
Buyback Yield %: 0.00
GF Value™: €0.02 vs. price of €0.01 (45% below fair value)
No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score
Get the complete analysis for STU:7EE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7EE has been successfully added to your 
